UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.301
AS - Asia 1.282
EU - Europa 1.193
SA - Sud America 220
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 6.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.277
SG - Singapore 491
CN - Cina 411
IT - Italia 327
RU - Federazione Russa 269
BR - Brasile 203
UA - Ucraina 177
IE - Irlanda 120
TR - Turchia 114
VN - Vietnam 106
DE - Germania 92
KR - Corea 83
SE - Svezia 54
FI - Finlandia 39
FR - Francia 27
DK - Danimarca 25
HK - Hong Kong 25
CA - Canada 18
GB - Regno Unito 18
NL - Olanda 16
AT - Austria 10
IN - India 10
AR - Argentina 8
CZ - Repubblica Ceca 7
BD - Bangladesh 6
UZ - Uzbekistan 6
EU - Europa 5
IQ - Iraq 5
PK - Pakistan 5
AU - Australia 4
GR - Grecia 4
MX - Messico 4
EC - Ecuador 3
EG - Egitto 3
MA - Marocco 3
VE - Venezuela 3
ZA - Sudafrica 3
ES - Italia 2
HN - Honduras 2
KE - Kenya 2
MY - Malesia 2
NP - Nepal 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CO - Colombia 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
JO - Giordania 1
JP - Giappone 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
QA - Qatar 1
SA - Arabia Saudita 1
TN - Tunisia 1
UG - Uganda 1
Totale 6.021
Salva come PNG Salva come JPEG
Città #
Ann Arbor 778
Chandler 360
Princeton 344
Woodbridge 334
Jacksonville 263
Houston 172
Singapore 141
Ashburn 136
Dublin 118
Beijing 110
Dong Ket 106
Izmir 106
Wilmington 102
Moscow 72
Nanjing 72
Andover 63
Pellezzano 44
Boardman 42
Naples 34
Fairfield 27
Salerno 27
Redwood City 26
Changsha 23
Hebei 23
Hong Kong 23
Norwalk 23
Shenyang 22
São Paulo 20
Washington 18
Jinan 17
Nanchang 17
Dearborn 16
The Dalles 15
Jiaxing 14
Nuremberg 13
Council Bluffs 12
Tianjin 12
Copenhagen 11
Dallas 11
Fisciano 10
Jinju 10
Milan 10
Nürnberg 10
Seattle 10
Guangzhou 9
Helsinki 9
Maletto 9
Ottawa 9
Pontecagnano 9
Amsterdam 8
Belo Horizonte 8
Cambridge 8
Haikou 8
Los Angeles 8
San Diego 8
Zhengzhou 8
Düsseldorf 7
Rome 7
Edmonton 6
Falls Church 6
Lappeenranta 6
Munich 6
San Mango Piemonte 6
Tashkent 6
Mestre 5
Brno 4
Frederiksberg 4
Fuzhou 4
Kunming 4
London 4
Napoli 4
Pompei 4
Porto Alegre 4
Pune 4
Redmond 4
Saint Petersburg 4
Simi Valley 4
Wuhan 4
Athens 3
Betim 3
Bolzano 3
Brasília 3
Caiazzo 3
Contagem 3
Daejeon 3
Dhaka 3
Falkenstein 3
Issum 3
Lanzhou 3
Latina 3
Manassas 3
New York 3
Nocera Inferiore 3
Raleigh 3
Rio de Janeiro 3
Salvador 3
San Giorgio A Cremano 3
Venezia 3
Vienna 3
Vila Velha 3
Totale 4.091
Salva come PNG Salva come JPEG
Nome #
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 132
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 130
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 123
Coeliac disease and C virus-related chronic hepatitis: a non association 115
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 113
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 104
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 104
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 103
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 101
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 101
Alcoholic Liver Disease and Hepatitis C Chronic Infection 98
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 93
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 93
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 92
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 91
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 90
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 89
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 83
Pharmacotherapy of alcoholic liver disease in clinical practice 82
Epidemiology and Natural History of Alcoholic Liver Disease 81
Lung ultrasound for diagnosis of pneumonia in emergency department 79
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 78
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 78
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 78
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 78
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 76
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 74
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 74
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 73
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 73
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 73
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 72
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 71
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 71
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 71
Non Alcoholic Fatty Liver: Epidemiology and Natural History 71
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 69
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 67
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 67
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 66
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 66
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 65
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 64
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 63
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 62
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 61
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 60
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 60
Adiponectin in hepatology 59
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 58
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 58
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 57
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 56
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 56
The diagnostic conundrum in non-alcoholic fatty liver disease 55
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 54
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 52
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 52
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 52
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 51
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 51
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 51
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 51
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 51
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 50
Viral hepatitis: Milestones, unresolved issues, and future goals 50
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 48
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 47
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 47
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 45
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 45
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 44
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 43
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 41
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 40
THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort 40
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 39
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 39
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 38
THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen 37
THU0289 PERSISTENCE OF CIRCULATING CRYOGLOBULINS AND RELATED SYMPTOMS AFTER HEPATITIS C VIRUS ERADICATION IN PATIENTS WITH MIXED CRYOGLOBULIN SYNDROME 37
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 36
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 35
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 33
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 32
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 31
Nutrigenomics and nutrigenetics in metabolic-(Dysfunction) associated fatty liver disease: Novel insights and future perspectives 29
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 27
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 27
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 26
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 26
The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials 26
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 25
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function 24
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 23
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial 23
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) 23
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 21
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 18
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 18
Totale 6.075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.735
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.735
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020114 0 0 0 0 0 0 0 0 0 0 83 31
2020/2021562 28 35 44 19 58 38 65 13 39 12 81 130
2021/2022609 6 6 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.248 32 29 23 53 106 165 272 150 284 106 28 0
Totale 6.277